Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting
Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.